Safety of Remimazolam in Vulnerable Populations
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s536873 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Jia-Yi Ge und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, People's Republic of China. Hauptthemen laut MEDLINE: Vulnerable Populations, Benzodiazepines, Hypnotics and Sedatives. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Vulnerable populations require careful consideration in drug selection due to their unique physiological conditions. Remimazolam, an innovative ultra-short-acting benzodiazepine, presents several advantages, including rapid onset, brief duration of action, and high predictability. Despite the extensive literature on remimazolam, few studies have specifically evaluated its safety in vulnerable patient populations. This review offers a comprehensive analysis of the safety profile of remimazolam in vulnerable populations, including cardiovascular diseases, neurological disorders, hepatic and renal dysfunction, respiratory conditions, metabolic disorders, rare diseases, and special groups such as the elderly and pediatric patients. It assesses recovery outcomes, hemodynamic stability, and adverse events such as respiratory depression and delirium. In our view, the prophylactic potential of remimazolam in these aspects may not be inferior to traditional anesthetic drugs (propofol, sevoflurane, etomidate, etc). and shows a trend of surpassing them in some aspects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, People's Republic of China.
ORCID-Profile: Bo-Ran Deng
Zitieren
APA
Ge, J. Y., Deng, B. R., Cao, X. H., & Liu, X. J. (2025). Safety of Remimazolam in Vulnerable Populations. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s536873
Vancouver
Ge JY, Deng BR, Cao XH, Liu XJ. Safety of Remimazolam in Vulnerable Populations. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s536873
BibTeX
@article{Ge2025,
author = {Ge, Jia-Yi and Deng, Bo-Ran and Cao, Xiao-Hua and Liu, Xing-Jun},
title = {Safety of Remimazolam in Vulnerable Populations},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s536873}
}
EUVIMED